DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,192 | +124.1% | 16,895 | +116.7% | 0.07% | +133.3% |
| Q2 2023 | $1,871 | +2428.4% | 7,795 | +2542.4% | 0.03% | +2900.0% |
| Q1 2023 | $74 | -7.5% | 295 | -2.3% | 0.00% | 0.0% |
| Q4 2022 | $80 | -99.9% | 302 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $78,000 | +1.3% | 302 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $77,000 | -80.6% | 302 | -77.7% | 0.00% | -83.3% |
| Q1 2022 | $397,000 | -16.9% | 1,354 | -6.7% | 0.01% | -14.3% |
| Q4 2021 | $478,000 | +8.1% | 1,452 | 0.0% | 0.01% | +16.7% |
| Q3 2021 | $442,000 | +6.2% | 1,452 | -6.4% | 0.01% | 0.0% |
| Q2 2021 | $416,000 | +19.2% | 1,552 | 0.0% | 0.01% | +20.0% |
| Q1 2021 | $349,000 | +2.3% | 1,552 | +1.1% | 0.01% | 0.0% |
| Q4 2020 | $341,000 | +3.0% | 1,535 | 0.0% | 0.01% | -16.7% |
| Q3 2020 | $331,000 | +11.1% | 1,535 | -8.9% | 0.01% | 0.0% |
| Q2 2020 | $298,000 | +27.9% | 1,685 | 0.0% | 0.01% | 0.0% |
| Q1 2020 | $233,000 | -10.0% | 1,685 | 0.0% | 0.01% | +50.0% |
| Q4 2019 | $259,000 | +10.7% | 1,685 | +4.0% | 0.00% | 0.0% |
| Q3 2019 | $234,000 | -73.3% | 1,620 | -73.5% | 0.00% | -69.2% |
| Q2 2019 | $875,000 | +308.9% | 6,120 | +277.8% | 0.01% | +333.3% |
| Q1 2019 | $214,000 | +28.1% | 1,620 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $167,000 | -24.8% | 1,620 | -20.7% | 0.00% | 0.0% |
| Q3 2018 | $222,000 | +9.9% | 2,044 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $202,000 | -50.2% | 2,044 | -50.7% | 0.00% | -40.0% |
| Q1 2018 | $406,000 | -26.0% | 4,144 | -30.0% | 0.01% | -28.6% |
| Q4 2017 | $549,000 | +1933.3% | 5,919 | +1755.5% | 0.01% | – |
| Q3 2017 | $27,000 | 0.0% | 319 | 0.0% | 0.00% | – |
| Q2 2017 | $27,000 | 0.0% | 319 | 0.0% | 0.00% | – |
| Q1 2017 | $27,000 | -6.9% | 319 | -13.6% | 0.00% | – |
| Q4 2016 | $29,000 | 0.0% | 369 | 0.0% | 0.00% | – |
| Q3 2016 | $29,000 | -21.6% | 369 | 0.0% | 0.00% | -100.0% |
| Q2 2016 | $37,000 | -11.9% | 369 | -16.1% | 0.00% | – |
| Q1 2016 | $42,000 | +110.0% | 440 | +100.0% | 0.00% | – |
| Q4 2015 | $20,000 | +5.3% | 220 | 0.0% | 0.00% | – |
| Q3 2015 | $19,000 | 0.0% | 220 | 0.0% | 0.00% | – |
| Q2 2015 | $19,000 | 0.0% | 220 | 0.0% | 0.00% | – |
| Q1 2015 | $19,000 | 0.0% | 220 | 0.0% | 0.00% | – |
| Q4 2014 | $19,000 | +11.8% | 220 | 0.0% | 0.00% | – |
| Q3 2014 | $17,000 | 0.0% | 220 | 0.0% | 0.00% | – |
| Q2 2014 | $17,000 | +6.2% | 220 | 0.0% | 0.00% | – |
| Q1 2014 | $16,000 | -5.9% | 220 | 0.0% | 0.00% | – |
| Q4 2013 | $17,000 | +13.3% | 220 | 0.0% | 0.00% | – |
| Q3 2013 | $15,000 | +7.1% | 220 | 0.0% | 0.00% | – |
| Q2 2013 | $14,000 | – | 220 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |